Medicines cost watchdog for England, the National Institute for Health and Clinical Excellence (NICE), has recommended Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Stelara (ustekinumab) in its Final Appraisal Determination (FAD) as a treatment option for patients with active psoriatic arthritis, when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
According to the FAD, ustekinumab is recommended as an option, alone or in combination with methotrexate, for treating active psoriatic arthritis in adults only when:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze